Guideline Video

Guideline Resources

  • Hematopoietic Cell Transplantation for Blastic Plasmacytoid Dendritic Cell Neoplasm
  • American Society for Transplantation and Cellular Therapy
  • August 18, 2026
  • Summary
  • Full-text

Video Transcription

Just published August 18th, 2026, the American Society for Transplantation and Cellular Therapy’s newest guideline on Hematopoietic Cell Transplantation for Blastic Plasmacytoid Dendritic Cell Neoplasm.

The purpose of this guideline was to develop contemporary recommendations to guide the clinical practice of hematopoietic cell transplantation in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). The guideline also intended for these recommendations to foster a deeper understanding and greater awareness of the clinical complexity of BPDCN.

In today’s rapid update, we’ll just be going over a summary of recommendations so for the full guideline, make sure to check it out on guidelinecentral.com

Let’s get started. 

  • The panel recommends a bone marrow (BM) aspirate, biopsy, flow cytometry, a positron emission tomography/computerized tomography (PET-CT), a diagnostic lumbar puncture (LP), and a thorough skin exam to confirm complete remission (CR) prior to proceeding with a hematopoietic cell transplantation (HCT). 
  • The panel recommends consolidation with an allogeneic HCT in patients with confirmed first complete remission (CR1). 
  • The panel suggests autologous HCT for patients in CR1 not considered fit for an allogeneic HCT provided that there is no evidence of BM involvement with BPDCN. 
  • The panel recommends consolidation with an allogeneic HCT in patients with confirmed CR2. 
  • The panel suggests autologous HCT for patients in CR2 not considered fit for an allogeneic HCT provided that there is no evidence of BM involvement with BPDCN. 
  • The panel does not recommend allogeneic HCT for patients with primary induction failure or active relapsed-refractory disease. 
  • The panel does not recommend autologous HCT for patients with primary induction failure or active relapsed-refractory disease. 
  • The panel suggests post-transplant intrathecal (IT) chemotherapy in all patients with BPDCN regardless of prior evidence of central nervous system involvement and/or residual central nervous system disease. 
  • The panel does not suggest maintenance/consolidative chemotherapy or targeted therapy to all patients with BPDCN who received an allogeneic HCT regardless of remission status at time of transplantation. 
  • The panel suggests maintenance/consolidative chemotherapy or targeted therapy only to patients who received an allogeneic HCT in CR2 or beyond. 
  • The panel does not recommend maintenance/consolidative chemotherapy or targeted therapy only in patients who received an allogeneic HCT using reduced intensity conditioning (RIC) regimens.
  • The panel does not recommend maintenance/consolidative chemotherapy or targeted therapy only in patients who received an autologous HCT.
  • The panel recommends disease surveillance sometime between days +30 and +90, at 6 months, at 1 year, at 18 months and at 2-year post-transplantation.
  • The panel recommends allogeneic HCT using a myeloablative conditioning (MAC) regimen with TBI for young and/or fit patients with BPDCN in CR1. 
  • The panel recommends allogeneic HCT using a RIC regimen for older and/or frail patients with BPDCN in CR1. 
  • The panel recommends allogeneic HCT using a MAC regimen with TBI for young and/or fit patients with BPDCN in CR2. 
  • The panel recommends allogeneic HCT using a RIC regimen for older and/or frail patients with BPDCN in CR2. 

And there you have it. Make sure to check out the full guideline from the American Society for Transplantation and Cellular Therapy and other related clinical decision support tools at guidelinecentral.com.

Sign up for alerts and stay informed on the latest published articles and guidelines.